Precigen Inc(PGEN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 7:59 PM ET (Korea 10/31 08:59)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.1 | Insider Own | 54.13% | Shs Outstand | 358.0M | Perf Week | 12.12% |
| Market Cap | 2.48B | Forward P/E | 11.14 | EPS next Y | 286.08% | Insider Trans | -0.68% | Shs Float | 164.2M | Perf Month | -15.47% |
| Enterprise Value | 2.54B | PEG | - | EPS next Q | 0.06 | Inst Own | 39.53% | Short Float | 28.25% | Perf Quarter | 4.99% |
| Income | -0.34B | P/S | 28.99 | EPS this Y | 111.78% | Inst Trans | 2.53% | Short Ratio | 8.87 | Perf Half Y | 70.1% |
| Sales | 0.09B | P/B | 57.02 | EPS next 5Y | - | ROA | -115.88% | Short Interest | 46.39M | Perf YTD | 66.03% |
| Book/sh | 0.12 | P/C | 65.03 | EPS past 3/5Y | -60.61% -6.02% | ROE | -837.08% | 52W High | -22.72% ($8.98) | Perf Year | 71.36% |
| Cash/sh | 0.11 | P/FCF | - | Sales past 3/5Y | -28.87% -37.7% | ROIC | -111.95% | 52W Low | 128.29% ($3.04) | Perf 3Y | 548.6% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -154.83% | Gross Margin | 89.19% | Volatility(W/M) | 7.65% 6.38% | Perf 5Y | 43.69% |
| Dividend TTM | - | EV/Sales | 29.69 | Sales Y/Y TTM | 1875.05% | Oper. Margin | -46.08% | ATR (14) | 0.44 | Perf 10Y | -72.99% |
| Dividend Ex-Date | - | Quick Ratio | 3.89 | EPS Q/Q | 153.95% | Profit Margin | -392.81% | RSI (14) | 50.29 | Recom | 1.5 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.58 | Sales Q/Q | 6322.66% | SMA20 | -0.03% ($6.94) | Beta | 0.98 | Target Price | $13.67 |
| Payout | - | Debt/Eq | 2.26 | Earnings | 2026/11/4 | SMA50 | -3.84% ($7.22) | Rel Volume | 1.55 | Prev Close | $6.64 |
| Employees | 160 | LT Debt/Eq | 2.23 | EPS/Sales Surpr. | 513.22% 96.47% | SMA200 | 31.7% ($5.27) | Avg Volume(3M) | 5.23M | Price | $6.94 |
| IPO | 2013/8/8 | Option/Short | Yes/Yes | Trades | 23333 | Volume | 8,103,164 | Change | 4.52% |
🧬 Precigen (PGEN) is a US biotech company developing differentiated novel therapeutics in immuno-oncology, autoimmune, and infectious disease areas, based on a gene and cell therapy platform. Having secured its first FDA-approved gene therapy for recurrent respiratory papillomatosis, the company is transitioning from the clinical stage to the commercial stage.
Over the past 1 year, roughly in the middle
23% below its 1-year high.
Traded more than usual. That is 155% of its average volume.
Next earnings report: November 4
3 days to go.
PGEN has weak earning power
Of every $100 in sales, $46.08 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +111.8% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $2,899. Peers typically go for $1,560. Compared with its own 1-year average, it is 24% pricier now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +43.7%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
28.3% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #81 of 597 in the industry
Based on market cap of $2B.
FAQ
What kind of company is PGEN?
PGEN belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of PGEN?
The market cap of PGEN is approximately $2.5B, ranking 1,892 within its sector.
What is the 52-week high and low for PGEN?
PGEN has recorded a 52-week high of $8.98 and a low of $3.04.
